Pharma BD Deal Intelligence

AstraZeneca PLC / Omniose, Inc.

2026 · Acquisition/Merger · Complete

AstraZeneca acquired Omniose, a St. Louis-based early-stage biotechnology company developing conjugate vaccines against serious bacterial infections, and folded the business into its infectious diseases unit. Financial terms were not disclosed. The acquisition follows a three-year exclusive research collaboration begun in January 2024, under which AstraZeneca held exclusive rights to Omniose's bioconjugation platform to explore vaccines against a range of bacterial pathogens including multidrug-resistant organisms. AstraZeneca describes the platform as a differentiated approach to engineering conjugate vaccines.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  AstraZeneca PLC deals